The development of more effective prevention and treatment strategies for solid tumors is limited by an incomplete understanding of the critical growth pathways that are activated in carcinogenesis. Signal transducers and activators of transcription (STAT) proteins have been linked to transformation and tumor progression. Several approaches have been used to block STAT3 in cancer cells resulting in reduced proliferation and apoptosis. We tested the hypothesis that blocking STAT3 activation using a transcription factor decoy approach would decrease tumor growth and STAT3 target gene expression in vivo. In a xenograft model of squamous cell carcinoma of the head and neck (SCCHN), daily administration of the STAT3 decoy (25 lg) resulted in decreased tumor volumes, abrogation of STAT3 activation, and decreased expression of STAT3 target genes (VEGF, Bcl-xL, and cyclin D1) compared to treatment with a mutant control decoy. Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. These results suggest that a transcription factor decoy approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN. Oncogene (2005) 24, 970-979.
Introduction
The family of signal transducers and activators of transcription (STAT) play a central role in signaling by numerous cytokines, polypeptide growth factors, and oncoproteins. STATs were initially described in the context of regulating physiologic cell signaling contributing to such diverse processes as differentiation, proliferation, and apoptosis. An increasing number of studies have implicated STAT activation, particularly STAT3, in transformation and tumor progression. Constitutive activation of STAT3 has been detected in many hematopoietic and solid malignancies, including multiple myeloma, leukemias, lymphomas, mycosis fungoides, as well as carcinomas of the prostate, breast, lung, pancreas, ovary and head and neck (GouilleuxGruart et al., 1996; Bowman et al., 2000; Grandis et al., 2000a; Huang et al., 2000; Garcia et al., 2001) .
Upon activation, STAT proteins dimerize and translocate to the nucleus where they regulate gene expression by binding to specific DNA response elements (Darnell, 1997) . To address directly the role of STAT3 as an oncogene, a constitutively active mutant of STAT3 was generated (STAT3C) and shown to induce transformation of fibroblasts and tumor formation in nude mice (Yu et al., 1995; Bromberg et al., 1999) . In addition to being a point of convergence for numerous oncogenic signaling pathways, STAT3 also participates in cell growth and survival. One of the first indications that STAT3 signaling contributes to malignancy, at least in part by preventing apoptosis, came from studies showing that increased expression of the antiapoptotic Bcl-2-family gene bcl-x L is dependent on constitutively activated STAT3 in multiple-myeloma cells (CatlettFalcone et al., 1999a) . Inhibition of STAT3 signaling blocked the expression of Bcl-x L in these tumor cells and sensitized them to FAS-mediated apoptosis (CatlettFalcone et al., 1999a) . Consistent with these findings, STAT3 activation has been shown to regulate Bcl-x L expression and apoptosis in a wide range of tumor cells (Bromberg et al., 1999; Grandis et al., 2000a; Niu et al., 2002) .
The association of STAT3 activation with transformation and tumor progression suggests that STAT3 may be an attractive molecular target for cancer therapy. Several strategies have been used to block the action of STAT proteins, including antisense methods, ectopic expression of dominant-negative mutants (Nakajima et al., 1996; Grandis et al., 1998; Li and Shaw, 2002) , inhibition of upstream kinases (Fry et al., 1994; Turkson et al., 1999; Kraker et al., 2000) , and phosphotyrosyl peptides (Turkson et al., 2001 ). An alternative approach to target the action of transcription factors, including STAT proteins, involves the use of double-stranded ''decoy'' oligonucleotides. The doublestranded DNA decoy closely corresponds to the response element within the promoter region of a responsive gene. By achieving a sufficient concentration of decoy in the target cells, the authentic interaction between a transcription factor and its endogenous response element in genomic DNA is impaired, with subsequent modulation of gene expression .
We previously reported that a transcription factor decoy approach could be used to decrease STAT3 activation and target gene expression in squamous cell carcinomas of the head and neck (SCCHN) in vitro (Leong et al., 2003) . The present study was undertaken to evaluate the therapeutic potential and mechanisms of the STAT3 decoy in a preclinical animal model of head and neck cancer. Intratumoral administration of the STAT3 decoy abrogated STAT3 activation and target gene expression in vivo where decreased tumor volumes in the STAT3 decoy-treated tumors were accompanied by increased apoptosis. Since STAT3 targeting alone is unlikely to be successful as monotherapy for cancer patients, we examined the potential benefit of combining the decoy with a standard chemotherapeutic agent used in this disease. Both in vitro and in vivo experiments demonstrated that the STAT3 decoy delivered in conjunction with cisplatin resulted in increased antitumor effects compared with either treatment alone. These results suggest that a transcription factor decoy approach may be used to block selectively STAT3 activation in tumors that are characterized by constitutive activation of this oncogenic transcription factor.
Results

STAT3 decoy inhibits SCCHN growth and induces apoptosis in vivo
Although nucleic acid-based approaches to target STAT3 have demonstrated encouraging results in tissue culture models, antitumor effects in vivo must be obtained to justify further clinical development. To determine the ability of the STAT3 decoy to block tumor growth, athymic nude mice, each bearing two SCCHN xenografts, were treated with daily injection of the STAT3 decoy (25 mg) (tumor on left flank) or injections of the mutant control decoy (25 mg) (tumor on right flank). The mutant control decoy differed from the STAT3 decoy by only a single base pair and was systematically derived from a series of mutations as described previously (Leong et al., 2003) . After approximately 10 treatments, the STAT3 decoy-treated tumors were growth inhibited compared with the controltreated tumors (P ¼ 0.002), an effect that persisted throughout treatment (Figure 1 ). Tumors were harvested at the conclusion of each experiment (25 treatments) and stained for apoptotic cells by TUNEL. Treatment with STAT3 decoy resulted in 3.25-fold increase in apoptosis compared with mutant control decoy-therapy (P ¼ 0.00038) (Figure 2 ). These results demonstrate that the STAT3 decoy inhibits SCCHN tumor growth in vivo, at least in part, by inducing apoptosis.
STAT3 decoy inhibits STAT3 activation and target gene expression in vivo
Mechanistic studies to evaluate the STAT3 decoy in vitro demonstrated that it worked by specifically inhibiting STAT3 activation and not by decreasing STAT3 expression or STAT3 tyrosine phosphorylation (Leong et al., 2003) . Blockade of STAT3 should abrogate gene expression of targets that control cell survival and proliferation. To determine the effects of the STAT3 decoy in vivo, xenografts were harvested 4 h after the last treatment and processed for EMSA. As shown in Figure 3 , treatment with the STAT3 decoy decreased STAT3 activation levels compared with treatment using the mutant control decoy (P ¼ 0.02). To demonstrate the specificity of the STAT3 decoy, the tumors were also analysed for STAT5 activation and no abrogation was detected (Figure 3b ). In addition, immunoblotting for cyclin D1 and Bcl-x L was performed to determine the effects of the STAT3 decoy on STAT3 target gene expression in vivo (Figures 3c and d ). An exact two-tailed Wilcoxon's test demonstrated a significant effect of the STAT3 decoy on Bcl-x L (P ¼ 0.0002) and cyclin D1 (P ¼ 0.0022) expression levels in the SCCHN xenografts treated with the STAT3 decoy compared to those tumors treated with the mutant control decoy. To optimize the STAT3 decoy for clinical application, we tested the antitumor mechanisms of the decoy combined with the chemotherapeutic agent cisplatin. SCCHN cells (1483) were treated with the mutant control decoy (25 mM), STAT3 decoy alone (25 mM), cisplatin alone (20 mM), or STAT3 decoy (25 mM) plus cisplatin (20 mM) followed by an Annexin 5-Cy3 apoptosis assay and fluorescence microscopy ( Â 40). The effects of the STAT3 decoy plus cisplatin on apoptosis were examined. As shown in Figure 4 , apoptosis was increased 2.6-fold in the SCCHN cells treated with cisplatin plus the STAT3 decoy compared with the decoy alone (P ¼ 0.00015).
As previously reported and shown above, treatment with the STAT3 decoy abrogates STAT3 target gene expression in vitro and in vivo (Leong et al., 2003) . To determine the effects of cisplatin in combination with the STAT3 decoy on STAT3 target gene expression, SCCHN cells were treated with the STAT3 decoy (or mutant control decoy), with or without cisplatin and harvested for immunoblotting ( Figure 5 ). The data were analysed using parametric analysis of variance of a twoway factorial design. In all three sets of experiments, the STAT3 decoy increased apoptosis and decreased cyclin D1 and Bcl-x L expression compared with the mutant control decoy (Po0.0001). Furthermore, the combination of the STAT3 decoy and cisplatin demonstrated an additive effect in all studies.
STAT3 decoy, alone and in combination with cisplatin, inhibits SCCHN growth, induces apoptosis, and inhibits STAT3 target gene expression in vivo
In an effort to maximize the therapeutic effects of the STAT3 decoy in vivo, the decoy was combined with cisplatin in a xenograft model of SCCHN. At 10 days after initiating therapy in established tumors, the group receiving STAT3 decoy combined with cisplatin was growth inhibited compared with STAT3 decoy combined with mutant control decoy or cisplatin alone, an effect that persisted throughout treatment ( Figure 6a ) (P ¼ 0.02). Tumors were harvested at the conclusion of each experiment (25 treatments) and stained for apoptotic cells by TUNEL (Figure 6b ). These results demonstrate that the STAT3 decoy combined with 
Discussion
Cumulative evidence supports a role for aberrant STAT3 activation in transformation and tumor progression. We previously demonstrated increased STAT3 activation in head and neck carcinogenesis, where STAT3 activity contributes to the loss of growth control by an antiapoptotic mechanism (Grandis et al., 2000b) . Targeting STAT3 with antisense oligonucleotides or dominant-negative mutants has resulted in apoptosis and modulation of STAT3-regulated genes in several cancer-derived cell lines including multiple myeloma, melanoma, mycosis fungoides, and SCCHN (CatlettFalcone et al., 1999b; Nielsen et al., 1999; Niu et al., 1999; Grandis et al., 2000a) . The present study provides evidence that STAT3 activation can be targeted in vivo using a transcription factor decoy approach with antitumor effects. Using a double-stranded oligomer with phosphorothioate modifications, we report inhibition of tumor growth, increased apoptosis, and abrogation of STAT3 target genes in an in vivo model of head and neck cancer. Furthermore, the addition of cisplatin to the STAT3 decoy increased antitumor effects in vitro and in vivo. These results support the development of the STAT3 decoy as a therapeutic strategy either alone or in combination with chemotherapy for head and neck cancer patients. One feature of an ideal cancer therapy is that it would specifically target tumor cells, without toxicity to normal cells. Stat3-null mice show an embryonic-lethal phenotype (Takeda et al., 1997) , which indicates a requirement for STAT3 signaling during early development. However, many studies that involve tissue-specific ablation of Stat3 have shown that Stat3-null nontumor cells proliferate and survive well in vivo and in vitro. These include Stat3
À/À macrophages, neutrophils, mammary cells, bone marrow progenitors, keratinocytes, and mouse embryonic fibroblasts (Akira, 2000; Levy and Darnell, 2002) . Numerous studies have shown that blocking constitutively activated STAT3 leads to inhibition of tumor cell growth and apoptosis of tumor Figure 4 Increased apoptosis of STAT3 decoy plus cisplatin in vitro. SCCHN cells (1483) were treated with mutant control decoy (25 mM, 6 days), STAT3 decoy alone (25 mM, 6 days), cisplatin alone (20 mM, 24 h), or STAT3 decoy (25 mM, 6 days) plus cisplatin (20 mM, 24 h) followed by an Annexin 5-Cy3 apoptosis assay and fluorescence microscopy ( Â 40) (P ¼ 00016)
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STAT3 decoy inhibits carcinogenesis in vivo S Xi et al cells Turkson et al., 2001; Leong et al., 2003) . We previously reported the lack of toxicity of the STAT3 decoy to normal mucosal epithelial cells despite incorporation of the decoy into these cells (Leong et al., 2003) . This selective inhibition might reflect an irreversible dependence of tumor cells on high levels of activated STAT3 for growth and survival, whereas normal cells might be able to withstand lower levels of STAT3 activity, or use alternative pathways for growth and survival. STAT3 regulates cell growth and survival, at least in part, by preventing apoptosis through increased expression of the antiapoptotic gene bcl-x L (Bromberg et al., 1999) . Inhibition of STAT3 signaling by various means decreased expression of Bcl-x L in tumor cells and sensitized them to FAS-mediated apoptosis (CatlettFalcone et al., 1999b; Nielsen et al., 1999; Niu et al., 1999; Grandis et al., 2000a) . In addition, many growth factor signaling pathways are known to regulate cell proliferation by enhancing the activity of cyclins, contributing to accelerated cell-cycle progression. Constitutive activation of STAT3 is associated with cyclin D1 upregulation (Bromberg et al., 1999) . In addition to cell proliferation and cell survival, angiogenesis is also required for tumor development. Most tumors cannot sustain their growth unless they are supplied with oxygen and nutrients from newly formed blood vessels (Hanahan and Folkman, 1996; Folkman, 1997; Hanahan and Weinberg, 2000; Rak et al., 2000) . One of the most potent angiogenesis-inducing signals is VEGF (Plate et al., 1992; Millauer et al., 1994; Grunstein et al., 1999) VEGF is usually produced by cancer cells at a high level compared with their normal counterparts. VEGF binds to transmembrane receptor tyrosine kinases on endothelial cells, and activates endothelial cell migration and proliferation to form new blood vessels (Veikkola and Alitalo, 1999; Veikkola et al., 2000) . STAT3 has been shown to be a direct transcriptional activator of the VEGF gene (Niu et al., 2002; Wei et al., 2003) . Transfection of cells with the constitutively activated mutant STAT3C is sufficient to increase VEGF expression and induce angiogenesis in vivo (Niu et al., 2002) . Blocking STAT3 signaling has been shown to inhibit SRC-and IL-6-induced VEGF upregulation (Niu et al., 2002; Wei et al., 2003) , and might therefore also abrogate the induction of VEGF by other tyrosine kinase pathways that lie upstream of STAT3.
We previously assessed the incorporation of the STAT3 decoy into SCCHN cells using fluorescencelabeled flow cytometry and found that the decoy was detected in a high percentage (>90%) of the cells examined (Leong et al., 2003) . In the present study, the STAT3 decoy demonstrated marked and reproducible effects on STAT3-mediated growth pathways in vivo. The profound effects of the decoy on proliferation and survival suggest that in addition to direct incorporation, an extracellular or secreted mechanism may be involved. The overall efficiency of action of the decoy is likely affected by many complex interacting factors including intracellular levels of the STAT3 decoy, levels of activated STAT3, the availability of target genes, and the relative affinities of the DNA response elements for STAT3. Optimization of the STAT3 decoy to enhance delivery to SCCHN cells should result in even more profound antitumor effects.
Transcription factor decoys have recently emerged as potential therapeutic tools for clinical application. Most transcription factors are necessary for cell viability so that stable expression of a dominant-negative transcription factor mutant is often unsuccessful. Use of transcription factor decoys has facilitated the study of transcription factors and their role in oncogenesis. Because transcription factors can recognize their relatively short binding sequences even in the absence of surrounding genomic DNA, short radiolabeled oligodeoxynucleotides (ODNs) bearing consensus binding sites can serve as probes in electrophoretic mobility shift assays (EMSAs), which identify and quantify transcription factor binding activity in nuclear extracts. More recently, ODNs bearing the consensus binding sequence of a specific transcription factor have been explored as tools for manipulating gene expression in living cells (Mann and Dzau, 2000) . This strategy involves the intracellular delivery of such 'decoy' ODNs, which are then recognized and bound by the target factor. Occupation of the transcription factor's DNA-binding site by the decoy renders the protein incapable of subsequently binding to the promoter regions of target genes. Bielinska et al. (1990) first described the use of such decoys as a tool for investigating the role of transcription factor activity in cell culture systems. Decoys can also be devised as therapeutic agents, either to inhibit the expression of genes that are transactivated by the factor in question or to upregulate genes that are transcriptionally suppressed by the binding of a factor. Kawamura et al. (1999) examined the role of NF-kB transactivation in tumor-induced cachexia in mice and found that intratumoral injection of NF-kB decoy ODN into colonic adenocarcinomas decreased food intake, body weight, and muscle mass. Decoy ODNs also offer a means to inhibit specifically other transcription factors in living cells, both for basic research into the molecular pathways involving these factors (Boccaccio et al., 1998; von Knethen et al., 1998; Bishop-Bailey and Hla, 1999; Takeuchi et al., 1999; Lim et al., 2000) and for novel drug development. Transcription factor decoys have been used to block STAT6 activation, which may be useful in reducing IL-4-induced proliferation of T-helper cells in allergic diseases (Wang et al., 2000) , as well as the cAMP response element-binding protein (CREB) in tumor cells (Park et al., 1999) .
STAT3 has been shown to be markedly elevated and abrogate apoptosis in head and neck squamous cell carcinomas compared with normal oral mucosa from patients without cancer (Leong et al., 2003) . A 15-mer STAT3 decoy that closely corresponds to the STAT3 response element within the c-fos promoter was constructed and shown to abrogate head and neck squamous cell carcinoma growth in vitro in a dosedependent manner (Leong et al., 2003) . In the present study, we demonstrated that blocking STAT3 activation Blockade of STAT3 with the STAT3 decoy also induced apoptosis, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. Multimodality therapy has emerged as the treatment of choice for most patients with solid tumors. Cisplatin has proven efficacy in the treatment of SCCHN and is a component of many combined therapeutic strategies (Mayer et al., 2003) . The potential advantages of combining the STAT3 decoy with chemotherapy include the nonoverlapping mechanisms and toxicity as well as the potential to reduce the dose of chemotherapy without abrogating antitumor effects. These results suggest that a transcription factor decoy therapeutic approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN.
Materials and methods
Cells
For both in vitro and the xenograft studies, we used the 1483 cell line, which is a well-characterized SCCHN cell line derived from a pharyngeal cancer that can form tumors in athymic nude mice . In culture, cells were maintained in supplemented DMEM (Cellgro, Washington, DC, USA) with 10% FBS (GIBCO/BRL, Grand Island, NY, USA) plus 100 U/ml penicillin and 100 U/ml streptomycin (GIBCO/ BRL).
STAT3 decoy and mutant control decoys
Phosphorothioated sense and antisense strands of STAT3 decoy and mutant control decoy oligonucleotides were designed and obtained from DNA Synthesis Facility, University of Pittsburgh (Pittsburgh, PA, USA) by means of bcyanothylphysphoramidite chemistry to minimize degradation of the oligonucleotides by endogenous nucleases. The STAT3 decoy sequence, based on the hSIE sequence, was 5 0 -CATTTCCCGTAAATC-3 0 , 3 0 GTAAAGGGCATTTAG-5 0 and the mutant control decoy sequence was 5 0 -CATTTCCCT TAAATC-3 0 , 3 0 -GTAAAGGGAATTTAG-5 0 . Sense and antisense strands were dissolved in Tris Á EDTA (pH 8.0) at a concentration of 900-1200 mM. Each sense-antisense pair was annealed by heating to 901C and decreasing the temperature by 51C increments every 15 min. After 3 h, the reaction mixture was held at a base temperature of 41C (Leong et al., 2003) .
Decoy plus cisplatin in vitro SCCHN cells (1483) were treated with mutant control decoy (25 mM), STAT3 decoy alone (25 mM), cisplatin alone (20 mM), or STAT3 decoy (25 mM) plus cisplatin (20 mM). Mutant control decoy or STAT3 decoy was always applied for a total of 6 days, and cisplatin was added for the last 24 h before harvesting. The effects of the STAT3 decoy plus cisplatin on apoptosis was assessed by an Annexin 5-Cy3 apoptosis assay (BioVision Research Products, 2455-D Old Middlefield Way, Mountain View, CA 94043, USA) and Bcl-x L and cyclin D1 were examined using immunoblotting as described below.
Immunoblotting
Whole-cell extracts were mixed with 2 Â sodium dodecyl sulfate (SDS) sample buffer (125 mmol/l Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 10% 2-mercaptoethanol) at 1 : 1 ratio and were heated for 5 min at 1001C. Proteins (50 mg/lane) were separated by 12.5% SDS-PAGE and transferred onto a nitrocellulose membrane (MSI, Westboro, MA, USA). Prestained molecular weight markers (GIBCO BRL, Gaithersburg, MD, USA) were included in each gel. Membranes were blocked for 30 min in Tris-buffered saline (TBS: 10 mmol/l Tris-HCl (pH 7.5) and 150 mmol/l NaCl) with 0.5% Tween-20 (TBST) and 5% BSA. After blocking, membranes were incubated with a primary antibody: rabbit anti-human VEGF polyclonal antibody, rabbit anti-human cyclin D1 polyclonal antibody, mouse anti-human Bcl-x L monoclonal antibody, or rabbit anti-human PCNA polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), in TBST and 1% BSA. After washing the membranes three times with TBST (5 min each), they were incubated with horseradish peroxidaseconjugated secondary antibody in TBST and 1% BSA for 30 min. Subsequently, membranes were washed three times with TBST and developed using the enhanced chemiluminescence (ECL) detection system (Amersham Life Sciences Inc., Arlington Heights, IL, USA). Quantitation of cyclin D1 and Bcl-x L was performed by using a Molecular Dynamics Personal Densitometer SI and IMAGEQUANT software (Image Products International, Chantilly, VA, USA). Immunoblotting bands were quantitated by densitometry and the Molecular Analyst software (AlphaDigidoc 1000, Alpho-Innotech) with normalization of each band to their corresponding loading control .
Electrophoretic mobility shift assay
Whole-cell extracts were prepared and EMSAs performed on 4% native polyacrylamide gels as described (Wong et al., 1994; Xi et al., 2003) . STAT3 activation was evaluated by using binding reactions with 20 mg of extracted protein, and radiolabeled high-affinity serum-inducible element (hSIE) duplex oligonucleotide was used to clone and characterize Figure 6 STAT3 decoy in combination with cisplatin inhibits SCCHN growth, induces apoptosis, and inhibits STAT3 target gene expression in vivo. (a) SCCHN cells were inoculated subcutaneously in the right and left flanks of athymic nude mice. After 10 days when the tumors were clearly palpable (approximately 2 mm in maximum diameter), mice were randomly assigned to treatment groups (STAT3 decoy, mutant control decoy, ciplatin alone, cisplatin plus STAT3 decoy, cisplatin plus mutant control decoy). There were 6-8 mice in each treatment group. Cisplatin (5 mg/kg) was injected intraperitoneally, and intratumoral injection of decoy (25 mg) in a volume of 50 ml was delivered daily. Tumor volumes were measured all over the course. At 10 days after initiating therapy in established tumors, the group receiving STAT3 decoy combined with cisplatin were growth inhibited compared with STAT3 decoy combined with mutant control decoy or cisplatin alone (P ¼ 0.02), an effect that persisted throughout treatment (a). (Wagner et al., 1990) . Quantitation of the STAT3 signal was performed by scanning the SIF-A band using a Molecular Dynamics Personal Densitometer SI and IMAGE-QUANT software. Normalization between blots was accomplished by running aliquots of U937 cell lysates (5 mg) that demonstrate activation of STAT3 on each gel. For supershift experiments, extracts were preincubated with STAT3 polyclonal antibody (C-20, Santa Cruz Biotechnology). Gel shift bands were quantitated by densitometry and the Molecular Analyst software (AlphaDigidoc 1000, Alpho-Innotech) with normalization of each band to the positive control lysate run on that gel as described by us previously for STAT3 activation determinations (Grandis et al., 2000a) .
In vivo tumor xenograft studies
Female athymic nude mice nu/nu (4-6 weeks old; 2072 g; Harlan-Sprague-Dawley) were implanted with 1 Â 10 6 1483 cells into the right and left flanks with a 26-gauge needle/1 ml tuberculin syringe resulting in two tumors per mouse. Approximately 10 days later, when the tumor nodules were established (E2 Â 2 mm in diameter), mice were randomly assigned to treatment groups (STAT3 decoy, mutant control decoy). There were 10 mice in each treatment group. Intratumoral injection of decoy (25 mg) in a volume of 50 ml was delivered. Mice were killed 25 days after daily injections, and tumors were harvested for analysis. In another series of experiments, mice were randomly assigned to treatment groups (STAT3 decoy, mutant control decoy, ciplatin alone, cisplatin plus STAT3 decoy, cisplatin plus mutant control decoy). There were 6-8 mice in each treatment group. Cisplatin (5 mg/kg) was injected intraperitoneally, and intratumoral injection of decoy (25 mg) in a volume of 50 ml was delivered as before. Animal care was in strict compliance with institutional guidelines established by the University of Pittsburgh, the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, 1996) , and the Association for Assessment and Accreditation of Laboratory Animal Care International.
In vitro apoptosis studies
Following treatment with STAT3 decoy plus cisplatin, SCCHN cells were detached by trypsinization, counted and pelleted (1000 r.p.m. for 5 min). Cell pellets were washed once with PBS (pH 7.4) and resuspended in 100 ml Annexin V binding buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 ). Cells (5 Â 10 5 ) were transferred to a 12 Â 75 mm tube and 5 ml of Annexin V-Cy3 (BioVision Research Products, 2455-D Old Middlefield Way, Mountain View, CA 94043, USA) was added per tube and allowed to incubate at room temperature for 15 min in the dark. Then the stained cell suspension was dropped on the slides and covered with coverslips. The membrane of apoptosis cells are stained a bright orange color when analysed with fluorescence microscope. The ratio (percentage) of apoptotic to total cells (apoptotic plus nonapoptotic cells) was calculated for each high-power field (HPF). For each treatment, 5-10 high-power fields of view were quantitated on each section.
In vivo apoptosis determinations
Detection and quantitation of apoptosis were performed by the TUNEL reaction, using the In Situ Cell Death Detection Kit, POD (Roche Diagnostics GmbH, Roche Applied Science, Sandhofer Strasse 116, D-68305 Mannheim, Germany). Cryostat sections were fixed in 4% paraformaldehyde in PBS for 30 min. After washing with PBS for 30 min, the sections were incubated in permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice. The sections were washed twice with PBS before the samples were incubated for 60 min at 371C with TUNEL reaction mixture to label DNA strand breaks with fluorescein-dUTP. After washing three times with PBS, the samples were incubated with Converter-POD for 30 min at 371C, washed again with PBS, and finally exposed to 0.025% 3,3 0 -diaminobenzidine (DAB)/0.01% H 2 O 2 in Tris-HCl buffer (pH 7.4) for 10 min. The number of apoptotic cells per HPF was counted. For each treatment, five samples were evaluated, and 5-10 fields of view were quantitated on each section.
Statistics
In vivo comparisons of stat3, cyclin D1 and Bcl-xl expression levels were conducted with the Wilcoxon's test for comparing two groups or the Kruskal-Wallis test for comparing three groups. All tests were exact and two-tailed. Studies of the joint effect of stat3 decoy and cisplatin upon in vitro apoptosis were evaluated with a two-way factorial design. Additive and synergistic effects of the STAT3 decoy and cisplatin were tested with a permutation test. In vivo tumor xenograft experiments were analysed with mixed linear models that assumed animals were random effects having an unstructured within-animal covariance matrix. Data were log transformed and examined for the interaction between treatment group and day of observation. Beginning with day 10 after tumor inoculation, differences between treatment groups were estimated and tested with the pooled estimated standard error. Multiple comparisons were controlled by simulating observations from a multivariate t distribution with the same covariance matrix as the observed data and adjusting P-values accordingly.
